MMP-2, MMP-9, and TIMP-4 and Response to Aspirin in Diabetic and Nondiabetic Patients with Stable Coronary Artery Disease: A Pilot Study.

Wiktor KuliczkowskiMarek RadomskiMariusz GąsiorJoanna UrbaniakJacek KaczmarskiAndrzej MysiakMarta Negrusz-KaweckaIwona Bil-Lula

Published in: BioMed research international (2017)

Aspirin-HPR did not affect the translocation and release of MMPs and TIMP-4 from platelets. TIMP-4 may serve as a marker of TXA2-mediated platelet aggregation. Chronically elevated plasma glucose increases plasma MMP-2, and HPR potentiates this phenomenon.

Keyphrases

coronary artery disease
cardiovascular events
low dose
cell migration
antiplatelet therapy
type diabetes
percutaneous coronary intervention
cardiovascular disease
acute coronary syndrome
anti inflammatory drugs
metabolic syndrome
aortic stenosis
transcatheter aortic valve replacement